Our mission is to transform pathology through AI-based tissue mining and standardization.
Visiopharm® is a world leader in AI-driven precision pathology software.
Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With highly advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 780 user accounts and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, Netherlands and the United States.
Privately-owned company
Visiopharm, a privately-owned company, was founded in 2002 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical Officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis.
100+
employees
100+
employees
20
support experts
20
support experts
19
software engineers
19
software engineers
52%
Masters & PhDs
52%
Masters & PhDs
16
nationalities
16
nationalities
Leading scientific advancement
Our solutions are featured in over 3300 scientific publications. Visiopharm is certified according to EN ISO 13485:2016, covering design, development, manufacture, installation, and service of in vitro diagnostics pathology software.
7
patents
7
patents
serving 19 of the top 20 big pharma companies
serving 19 of the top 20 big pharma companies
+3500
scientific publications
+3500
scientific publications
Technology & AI
Our company has grown into an international business with over 750 accounts in more than 40 countries. Our growing network of authorized distributors and partners support the growth of Visiopharm’s solutions on several continents including North America, Europe, and Asia.
+120
ready-to-use APPS
+120
ready-to-use APPS
8
CE-IVD APPs
8
CE-IVD APPs
100%
rooted in AI
100%
rooted in AI
Our timeline
Key moments from 20 years of transforming pathology through AI-based image analysis and workflow standardisation.
Awards and Certificates
Frost & Sullivan – Global Digital Pathology Solutions 2019
Visiopharm Earns Acclaim from Frost & Sullivan for Transforming Anatomic Pathology. Frost & Sullivan recognizes Denmark-headquartered Visiopharm A/S with the 2019 Global Company of the Year Award. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
CIO Applications Top 25 Machine Learning Solution Providers 2019
Visiopharm was recognized by CIO Applications Magazine as CIO Applications Top 25 Machine Learning Solution Provider 2019. CIO Applications brings you the “Top 25 Machine Learning Solution Providers – 2019”. The CIO Application Magazine states: “The list features some of the most prominent machine solution providers in the industry that have excelled in their services and product portfolio in the ML space”.
Børsen Gazelle Growth Accelerator Award
Visiopharm wins Denmark’s leading business newspaper “Dagblade Børsen” Gazelle Growth Accellerator, the prestigious award “Børsen Gazelle 2017” as an identification of Denmark’s absolute growth elite.
The award is given as a recognition to achieve a continuous growth in revenue or gross profit for the last four financial years, and which has, in total, more than doubled the revenue or the gross profit in the period.
Danish EY Entrepreneur Of The Year™
Visiopharm was promoted two times for EY Entrepreneur of the Year in 2016 and 2017. We were placed among the top three nominees for the finalist in the Life Science category in 2017.
Ernst & Young, EY Entrepreneur Of The Year™ awards recognize and celebrate unstoppable entrepreneurs in their field.